Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chen Hu

Showing results (1021-1030 of 1,174) with videos related to

Pageof 118
Sort By:
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|March 14, 2021
Increased Th22 cell numbers in a general pediatric population with filaggrin haploinsufficiency: The Generation R StudyKirsten I M Looman, Minke M F van Mierlo, Menno C van Zelm, et al.
Nano-Micro Letters|February 16, 2024
The Roadmap of 2D Materials and Devices Toward ChipsAnhan Liu, Xiaowei Zhang, Ziyu Liu, et al.
Acta Pharmacologica Sinica|March 1, 2022
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancersJiang-Yan Cao, Shuang Qi, Hong Wu, et al.
Cell Death & Disease|May 9, 2020
The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53Chen Hu, Mu Zhang, Niko Moses, et al.
JMIR Mhealth and Uhealth|March 31, 2025
Accelerometry-Assessed Physical Activity and Circadian Rhythm to Detect Clinical Disability Status in Multiple Sclerosis: Cross-Sectional StudyNicole Bou Rjeily, Muraleetharan Sanjayan, Pratim Guha Niyogi, et al.
Cancer Letters|January 27, 2019
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical modelsTingting Lu, Cheng Chen, Aoli Wang, et al.
Investigational New Drugs|December 25, 2019
Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia modelsLi Wang, Chen Hu, Aoli Wang, et al.
Annals of Clinical and Translational Neurology|September 5, 2025
Long COVID in People With Multiple Sclerosis and Related Disorders: A Multicenter Cross-Sectional StudyChen Hu, Jiyeon Son, Lindsay McAlpine, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|July 18, 2024
Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study)Wenjue Zhang, Yuan Tang, Lichun Wei, et al.
Journal of Medicinal Chemistry|May 4, 2019
Discovery of ( E)- N<sup>1</sup>-(3-Fluorophenyl)- N<sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1 H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)Xuesong Liu, Beilei Wang, Cheng Chen, et al.
Pageof 118

Showing results (1021-1030 of 1,174) with videos related to

Sort By:
Pageof 118
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|March 14, 2021
Increased Th22 cell numbers in a general pediatric population with filaggrin haploinsufficiency: The Generation R StudyKirsten I M Looman, Minke M F van Mierlo, Menno C van Zelm, et al.
Nano-Micro Letters|February 16, 2024
The Roadmap of 2D Materials and Devices Toward ChipsAnhan Liu, Xiaowei Zhang, Ziyu Liu, et al.
Acta Pharmacologica Sinica|March 1, 2022
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancersJiang-Yan Cao, Shuang Qi, Hong Wu, et al.
Cell Death & Disease|May 9, 2020
The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53Chen Hu, Mu Zhang, Niko Moses, et al.
JMIR Mhealth and Uhealth|March 31, 2025
Accelerometry-Assessed Physical Activity and Circadian Rhythm to Detect Clinical Disability Status in Multiple Sclerosis: Cross-Sectional StudyNicole Bou Rjeily, Muraleetharan Sanjayan, Pratim Guha Niyogi, et al.
Cancer Letters|January 27, 2019
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical modelsTingting Lu, Cheng Chen, Aoli Wang, et al.
Investigational New Drugs|December 25, 2019
Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia modelsLi Wang, Chen Hu, Aoli Wang, et al.
Annals of Clinical and Translational Neurology|September 5, 2025
Long COVID in People With Multiple Sclerosis and Related Disorders: A Multicenter Cross-Sectional StudyChen Hu, Jiyeon Son, Lindsay McAlpine, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|July 18, 2024
Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study)Wenjue Zhang, Yuan Tang, Lichun Wei, et al.
Journal of Medicinal Chemistry|May 4, 2019
Discovery of ( E)- N<sup>1</sup>-(3-Fluorophenyl)- N<sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1 H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)Xuesong Liu, Beilei Wang, Cheng Chen, et al.
Pageof 118